Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in The First-Line Treatment of Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

NCT06092086 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT06092086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06092086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in The First-Line Treatment of Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Phase 2
Overall status
Recruiting
Start date
August 18, 2023
Completion date
August 1, 2030
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk positive non-small cell lung cancer